Jury awards Natera $96M+ in blood test patent fight
CareDx said it will fight a $96 million jury verdict in the company’s years-long patent battle with Natera over their rival kidney transplant rejection tests.
A Delaware jury on Friday determined that CareDx infringed on one of two patents at the center of a 2020 case accusing the company of “blatant infringement” of Natera’s cell-free DNA technology. The jury awarded $96.2 million in damages, including lost profits of $83.7 million and past royalties of $12.5 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.